Valuation dashboard for Johnson & Johnson (JNJ) with P/E 30.82, P/B 7.66, EV/EBITDA 19.87 and dividend yield 1.98%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
Analysis Summary
Johnson & Johnson reported revenue of $94.19B in the most recent fiscal year, growing at a 5-year CAGR of 2.7%. Net income reached $26.80B, with a 12.7% 5-year CAGR.
Trailing-twelve-month margins: gross margin 70.5%, operating margin 26.8%, net margin 21.5%.
At the current price of $267.28, JNJ trades at a P/E of 30.82 and an ROE of 25.74%. Market capitalisation stands at $644.1B, placing it among large-cap names.
Balance sheet quality for JNJ: current ratio of 1.0. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| P/E Ratio | 30.82 |
| Price / Book | 7.66 |
| EV / EBITDA | 19.87 |
| Dividend Yield | 1.98% |
Valuation Models
| DCF Fair Value | $282.96 |
| vs Current Price | +5.9% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| JNJ | Johnson & Johnson | $644.1B | 30.82 | 7.66 | 25.7% |
| MRK | Merck & Co., Inc. | $355.5B | 115.04 | 8.54 | 6.6% |
| AMGN | Amgen Inc. | $203.1B | 23.20 | 17.39 | 89.3% |
| GILD | Gilead Sciences, Inc. | $183.4B | 15.77 | -16.3% | |
| ABBV | AbbVie Inc. | $445.7B | 73.77 | -129.2% | |
| AZN | AstraZeneca PLC | $252.6B | 25.10 | 5.17 | 21.7% |
| NVS | Novartis AG | $263.6B | 21.26 | 6.41 | 29.6% |
| NVO | Novo Nordisk A/S | $185.3B | 9.72 | 5.10 | 59.1% |
Price
| Price | $267.28 |
| Market Cap | $644.1B |
| Exchange | NYSE |
| Country | US |
Profitability
| Return on Equity | 25.74% |
| Return on Invested Capital | 13.89% |
| Return on Assets | 10.46% |
| Gross Margin | 70.45% |
| Operating Margin | 26.81% |
| Net Margin | 21.48% |
Related companies: ABBV · AMGN · AZN · GILD · MRK · NVO · NVS
Explore sector: Healthcare · Drug Manufacturers - General
More sections of JNJ: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks